BioMarin Pharmaceutical valuation
Valuation
The P/E ratio is 146.8. The average price target of 27 analysts is $90.78.
Data as of November 15, 2026
BioMarin Pharmaceutical compared with similar companies
BioMarin Pharmaceutical's P/E (trailing 12 months): 146.8, +168% against the median of a group of 7 similar companies (54.8).
| Metric | BioMarin Pharmaceutical | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 146.8 | 54.8 | 22.9 – 69.1 | High |
| Forward P/E | 9.05 | 15.4 | 9.36 – 25.0 | Low |
| EV/EBITDA | 17.0 | 17.0 | 13.8 – 40.7 | Middle |
| Price/book | 1.77 | 10.1 | 6.26 – 19.0 | Low |
| Price/sales | 3.03 | 8.80 | 6.44 – 13.7 | Low |
| Gross margin | 53.2% | 91.1% | 59.7% – 93.1% | Low |
| Operating margin | 16.3% | 16.3% | -12.6% – 29.2% | Middle |
| Net margin | -0.5% | 4.4% | -12.9% – 21.9% | Middle |
| ROE | -0.3% | 8.3% | -9.7% – 38.5% | Middle |
| Debt/equity | 0.67 | 0.13 | 0.06 – 0.67 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
BioMarin Pharmaceutical: valuation over time
On the latest fiscal year's earnings (2025), BioMarin Pharmaceutical's P/E today is 32.3, in line with the median of its last 5 fiscal years (33.0; between 19.5 and 138.0 from 2020 to 2025). Relative to earnings, it costs about the same as in the past.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $59.43 | $1.80 | 33.0 |
| 2024 | $65.73 | $2.21 | 29.7 |
| 2023 | $96.42 | $0.87 | 110.8 |
| 2022 | $103.49 | $0.75 | 138.0 |
| 2021 | $88.35 | -$0.35 | — |
| 2020 | $87.69 | $4.50 | 19.5 |
| 2019 | $84.55 | -$0.13 | — |
| 2018 | $85.15 | -$0.44 | — |
| 2017 | $89.17 | -$0.67 | — |
| 2016 | $82.84 | -$3.81 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $11.09B
- Enterprise value
- $14.54B
- PEG
- 0.52
- EV/revenue
- 3.98
Profitability and growth
- ROA
- 3.9%
- ROIC
- 3.6%
- Revenue growth (year over year)
- 32.0%
- Earnings growth (year over year)
- -81.3%
Financial health
- Total cash
- $736.01M
- Total debt
- $4.19B
- Current ratio
- 2.44
- Quick ratio
- 1.13
- Altman Z-Score
- 2.00
- Piotroski F-Score
- 3.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $90.78
- Median price target
- $89.00
- High price target
- $120.00
- Low price target
- $60.00
- Analysts with a price target
- 27
- Consensus
- Buy
- Forward EPS
- $6.32
- EPS estimate, current year
- $3.03
Shares and trading
- Beta
- 0.23
- Average volume
- 2.2M
- Shares outstanding
- 193.69M
- Float
- 192.75M
- Institutional ownership
- 104.4%
- Insider ownership
- 1.1%
- Short interest (% of float)
- 7.3%
- Short ratio (days)
- 5.73
